February 16, 2021: “Novartis announced new multicenter survey results showing that people living with multiple sclerosis (MS) and nurses prefer the Sensoready® autoinjector pen for self-administration of Kesimpta® (ofatumumab) over other autoinjectors used for other disease-modifying therapies in MS.
These data, which will be presented at the sixth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum (ACTRIMS) taking place on February 25-27, 2021, continue to show that Kesimpta has the potential to become a first-choice treatment option, as ease of administration plays an important role in patient satisfaction and treatment adherence.
“As an MS nurse, it’s important for me to know that the people I work with who have MS are going to be successful in administering their treatment themselves,” said Amy Perrin Ross.
“The Sensoready autoinjector pen is easy to set up and use, so people living with MS can feel confident that they will be able to administer the treatment themselves independently and comfortably.”
“For people living with a chronic disease such as MS, access to highly effective treatments and maintaining flexibility in their lives is paramount,” said Estelle Vester-Blokland, Global Head Neuroscience Medical Affairs, Novartis Pharmaceuticals.
“At Novartis, we are committed to reimagining medicine and solutions that enable patients to maintain that flexibility in their daily lives by having a safe, high efficacy treatment that is easy to use independently from the comfort of their own home.”
About the study
The multicenter survey was conducted with 80 MS patients and 50 MS nurses across the US, Germany, France and Italy.
The survey included patients with RMS who received a disease-modifying treatment through a subcutaneous/intramuscular injection via an autoinjector for ≥2 months and MS nurses who had ≥3 years of practice with experience in training patients on ≥2-6 MS autoinjector devices.
Nurses and patients were asked a set of qualitative open-ended and quantitative closed-ended questions, rating the importance of predefined attributes for the Sensoready autoinjector pen versus other autoinjectors (Rebidose/Rebismart [Rebif], Avonex pen [Avonex], Autoject/YpsoMate [Copaxone], Plegridy pen [Plegridy]).
The answers were measured on a Likert scale from 1 (not at all important) to 10 (extremely important).
This study will be presented at the ACTRIMS Forum 2021 on February 25-27, 2021.”
